LX1001 is being evaluated in an open‐label, dose‐escalation Phase 1/2 clinical trial in APOE ε4 homozygous individuals who are 50 years of age or older and have mild cognitive impairment (MCI) to moderate dementia and biomarkers consistent with AD. The gene discussed is APOE; the disease is Alzheimer disease.